Lung function in patients receiving busulphan

Area of Science:

• Pulmonary Medicine
• Toxicology
• Oncology

Background:

• Busulphan is a chemotherapy agent used in treating certain cancers.
• Busulphan-induced lung injury, specifically fibrosing alveolitis, is a known but not fully understood complication.
• Early detection of busulphan lung is crucial for patient management.

Purpose of the Study:

• To investigate methods for earlier detection of busulphan lung (fibrosing alveolitis).
• To determine the incidence of busulphan lung in patients undergoing treatment.
• To explore the relationship between busulphan dosage and the development of fibrosing alveolitis.

Main Methods:

• Serial clinical, radiological, and physiological studies were conducted.
• Measurement of the gas transfer factor was used as a key physiological indicator.
• Twenty-three patients receiving busulphan treatment were monitored over an average of two years.

Main Results:

• One case of busulphan lung was detected and confirmed post-mortem.
• No clinical, radiological, or physiological evidence of fibrosing alveolitis was found in the remaining 22 patients.
• The incidence of busulphan lung in this cohort was low.

Conclusions:

• The development of busulphan lung (fibrosing alveolitis) may be influenced by individual genetic or immunological factors.
• Busulphan dosage alone may not be the primary determinant for developing this lung toxicity.
• Further research is needed to elucidate the specific mechanisms underlying busulphan-induced fibrosing alveolitis.